Generation of SIV-resistant T cells and macrophages from nonhuman primate induced pluripotent stem cells with edited CCR5 locus

[1]  Michele K. Anderson,et al.  DL4-μbeads induce T cell lineage differentiation from stem cells in a stromal cell-free system , 2021, Nature Communications.

[2]  H. Akari,et al.  Generation of macrophages with altered viral sensitivity from genome-edited rhesus macaque iPSCs to model human disease , 2021, Molecular therapy. Methods & clinical development.

[3]  T. Shinohara,et al.  A clinically applicable and scalable method to regenerate T-cells from iPSCs for off-the-shelf T-cell immunotherapy , 2021, Nature Communications.

[4]  N. Kadowaki,et al.  High Frequency Production of T Cell-Derived iPSC Clones Capable of Generating Potent Cytotoxic T Cells , 2019, Molecular therapy. Methods & clinical development.

[5]  Bin Zhang,et al.  CRISPR-Edited Stem Cells in a Patient with HIV and Acute Lymphocytic Leukemia. , 2019, The New England journal of medicine.

[6]  D. Guo,et al.  CCR5 editing by Staphylococcus aureus Cas9 in human primary CD4+ T cells and hematopoietic stem/progenitor cells promotes HIV-1 resistance and CD4+ T cell enrichment in humanized mice , 2019, Retrovirology.

[7]  I. Slukvin,et al.  NOTCH Activation at the Hematovascular Mesoderm Stage Facilitates Efficient Generation of T Cells with High Proliferation Potential from Human Pluripotent Stem Cells , 2019, The Journal of Immunology.

[8]  P. Hanley,et al.  HIV-Specific, Ex Vivo Expanded T Cell Therapy: Feasibility, Safety, and Efficacy in ART-Suppressed HIV-Infected Individuals. , 2018, Molecular therapy : the journal of the American Society of Gene Therapy.

[9]  C. Cruz,et al.  HIV-Specific T Cells Generated from Naive T Cells Suppress HIV In Vitro and Recognize Wide Epitope Breadths. , 2018, Molecular therapy : the journal of the American Society of Gene Therapy.

[10]  A. Scharenberg,et al.  Engineering HIV-Resistant, Anti-HIV Chimeric Antigen Receptor T Cells. , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[11]  H. Nakauchi,et al.  'Off-the-shelf' immunotherapy with iPSC-derived rejuvenated cytotoxic T lymphocytes. , 2017, Experimental hematology.

[12]  S. Ogawa,et al.  Regeneration of CD8αβ T Cells from T-cell-Derived iPSC Imparts Potent Tumor Antigen-Specific Cytotoxicity. , 2016, Cancer research.

[13]  P. Hsu,et al.  Methods for Optimizing CRISPR-Cas9 Genome Editing Specificity. , 2016, Molecular cell.

[14]  J. Xu,et al.  Different Effects of sgRNA Length on CRISPR-mediated Gene Knockout Efficiency , 2016, Scientific Reports.

[15]  Fumito Ito,et al.  Adoptive Transfer of CD8+ T Cells Generated from Induced Pluripotent Stem Cells Triggers Regressions of Large Tumors Along with Immunological Memory. , 2016, Cancer research.

[16]  S. Kaneko,et al.  Reprogramming away from the exhausted T cell state. , 2016, Seminars in immunology.

[17]  J. Thomson,et al.  GSK3β Inhibition Promotes Efficient Myeloid and Lymphoid Hematopoiesis from Non-human Primate-Induced Pluripotent Stem Cells , 2016, Stem cell reports.

[18]  J. Hauber,et al.  mRNA transfection of a novel TAL effector nuclease (TALEN) facilitates efficient knockout of HIV co-receptor CCR5 , 2015, Nucleic acids research.

[19]  David Bryder,et al.  Efficient ablation of genes in human hematopoietic stem and effector cells using CRISPR/Cas9. , 2014, Cell stem cell.

[20]  Claudio Mussolino,et al.  TALENs facilitate targeted genome editing in human cells with high specificity and low cytotoxicity , 2014, Nucleic acids research.

[21]  Wei-Ting Hwang,et al.  Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. , 2014, The New England journal of medicine.

[22]  J. Keith Joung,et al.  Improving CRISPR-Cas nuclease specificity using truncated guide RNAs , 2014, Nature Biotechnology.

[23]  Luke A. Gilbert,et al.  Dynamic Imaging of Genomic Loci in Living Human Cells by an Optimized CRISPR/Cas System , 2013, Cell.

[24]  Melisa L. Budde,et al.  Adoptive Transfer of Lymphocytes Isolated from Simian Immunodeficiency Virus SIVmac239Δnef-Vaccinated Macaques Does Not Affect Acute-Phase Viral Loads but May Reduce Chronic-Phase Viral Loads in Major Histocompatibility Complex-Matched Recipients , 2013, Journal of Virology.

[25]  S. Lam,et al.  T-cell therapies for HIV. , 2013, Immunotherapy.

[26]  Hiroshi Kawamoto,et al.  Regeneration of human tumor antigen-specific T cells from iPSCs derived from mature CD8(+) T cells. , 2013, Cell stem cell.

[27]  Haruhiko Koseki,et al.  Generation of rejuvenated antigen-specific T cells by reprogramming to pluripotency and redifferentiation. , 2013, Cell stem cell.

[28]  Melisa L. Budde,et al.  Characterization of Mauritian cynomolgus macaque major histocompatibility complex class I haplotypes by high-resolution pyrosequencing , 2010, Immunogenetics.

[29]  D. Watkins,et al.  Synchronous infection of SIV and HIV in vitro for virology, immunology and vaccine-related studies , 2010, Nature Protocols.

[30]  S. Mummidi,et al.  CCR5 Expression Levels Influence NFAT Translocation, IL-2 Production, and Subsequent Signaling Events during T Lymphocyte Activation1 , 2009, The Journal of Immunology.

[31]  C. Apetrei,et al.  In vitro characterization of primary SIVsmm isolates belonging to different lineages. In vitro growth on rhesus macaque cells is not predictive for in vivo replication in rhesus macaques. , 2007, Virology.

[32]  D. O’Connor,et al.  Simian Immunodeficiency Virus SIVmac239 Infection of Major Histocompatibility Complex-Identical Cynomolgus Macaques from Mauritius , 2006, Journal of Virology.

[33]  R. Desrosiers,et al.  Mechanisms for Adaptation of Simian Immunodeficiency Virus to Replication in Alveolar Macrophages , 2000, Journal of Virology.

[34]  D. Ho,et al.  Natural Infection of a Homozygous Δ24 CCR5 Red-capped Mangabey with an R2b-Tropic Simian Immunodeficiency Virus , 1998, The Journal of experimental medicine.

[35]  B. Torbett,et al.  Differential Tropism and Replication Kinetics of Human Immunodeficiency Virus Type 1 Isolates in Thymocytes: Coreceptor Expression Allows Viral Entry, but Productive Infection of Distinct Subsets Is Determined at the Postentry Level , 1998, Journal of Virology.

[36]  Marc Parmentier,et al.  Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene , 1996, Nature.

[37]  Richard A Koup,et al.  Homozygous Defect in HIV-1 Coreceptor Accounts for Resistance of Some Multiply-Exposed Individuals to HIV-1 Infection , 1996, Cell.

[38]  P. Sehgal,et al.  Characterization of infectious molecular clones of simian immunodeficiency virus (SIVmac) and human immunodeficiency virus type 2: persistent infection of rhesus monkeys with molecularly cloned SIVmac , 1988, Journal of virology.

[39]  B. Torbett,et al.  CCR5 Disruption in Induced Pluripotent Stem Cells Using CRISPR/Cas9 Provides Selective Resistance of Immune Cells to CCR5-tropic HIV-1 Virus. , 2015, Molecular therapy. Nucleic acids.

[40]  D. O’Connor,et al.  Haplessly hoping: macaque major histocompatibility complex made easy. , 2013, ILAR journal.